Innate Pharma S.A.
IPHA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.32 | -0.17 | -0.00 |
| FCF Yield | -5.06% | -16.38% | -7.31% | -18.74% |
| EV / EBITDA | -2.32 | -99.16 | -19.16 | -6.00 |
| Quality | ||||
| ROIC | -59.43% | -8.77% | -34.05% | -21.90% |
| Gross Margin | 100.00% | 10.83% | 10.42% | -184.12% |
| Cash Conversion Ratio | 0.14 | 4.30 | 0.33 | 1.11 |
| Growth | ||||
| Revenue 3-Year CAGR | -39.74% | 62.43% | -6.15% | -44.00% |
| Free Cash Flow Growth | 79.13% | -72.17% | 66.09% | 5.23% |
| Safety | ||||
| Net Debt / EBITDA | 0.75 | 16.70 | 3.42 | 1.38 |
| Interest Coverage | -91.12 | -19.80 | -199.39 | -153.29 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 47.52 | 271.16 | -76.60 | -64.35 |